mynth
← DATABASE
06/2026MajorityLBO

Motion Equity Partners takes majority stake in Polaris

FRANCE Life Sciences / Nutrition & Dietary Supplements REV €50–100M

Context

Motion Equity Partners has acquired a majority stake in Polaris, a leading manufacturer of omega-3 concentrates, from Demea Agro, which had invested in the company three years ago. This transaction is part of a broader strategy to drive external growth and international expansion, with ambitious plans to establish a US-based industrial site and double in size within the next five years. Historical shareholders of Polaris, including Cerea Partners, Seventure, and Picama, are reinvesting alongside Motion Equity Partners, which brings its expertise in supporting industrial companies in their international development. This deal enables Demea Agro to achieve a 3.5x return on its initial investment, with an internal rate of return (IRR) of 50%. The acquisition also strengthens Motion Equity Partners' portfolio of investments in high-growth industrial businesses. Legal and financial advisory services were provided by GCA, Eight Advisory, Forvis Mazars, Goodwin, and BDO.

Polaris, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x in 2026).

-> Deep-dive in Healthcare & Pharma market trends

Target

Polaris, established in 1994, is a specialized company that produces high-quality microalgae-based omega-3 concentrates for the dietary supplement, infant nutrition, and cosmetics industries. This Brittany-based enterprise has developed a unique expertise in lipid chemistry, enabling the transformation of crude oils into premium concentrates using proprietary technologies such as QualitySilver and GreenSilver. These complex processes ensure unparalleled product quality, combining high concentration, superior organoleptic properties, and resistance to oxidation. With a significant international presence, accounting for two-thirds of its revenue, Polaris holds a strategic position in a resilient and dynamic market.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2025
€50–100M
[members only]
[members only]
2024
€50–100M
[members only]
[members only]

Other operations with Motion Equity Partners

Other operations with Motion Equity Partners
DateAcquirerTargetCountrySector
10/2023MOTION EQUITY PARTNERSBANOOKFRANCECRO / Clinical Trials
10/2022MOTION EQUITY PARTNERSTOURNAIREFRANCEMetal Packaging
05/2018MOTION EQUITY PARTNERSHOLWEG WEBERUNITED STATESRobotics & Automation

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
07/2026APHEONTEKNIMEDFRANCEImplants & Prosthetics
07/2026HALMADREAMPATH DIAGNOSTICSFRANCEDiagnostic Equipment
06/2026COLUMBUS VENTURE PARTNERS / MERIEUX EQUITY PARTNERSONA THERAPEUTICSSPAINR&D Biotech
06/2026ABBVIEAPOGEE THERAPEUTICSUNITED STATESR&D Biotech
06/20263ILABORATOIRE NUTERGIAFRANCENutrition & Dietary Supplements
06/2026BRIDGEPOINTOBAGI MEDICALUNITED STATESGenerics / Labs
06/2026DHCAREOTTOBOCK HUMAN MOBILITYGERMANYMedical Devices
06/2026CORDENPHARMAAMBIOPHARMUNITED STATESCDMO
05/2026STRYKERAMPLITUDE VASCULAR SYSTEMSUNITED STATESMedical Devices
04/2026ASTORGTHERMO FISHER MICROBIOLOGYUNITED STATESDiagnostic Equipment

REFERENCES

Revenue range: REV €50–100M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Polaris by Motion Equity Partners are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: polaris

Acquirer: motion equity partners

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Polaris, a French company specialised in Nutrition & Dietary Supplements, by Motion Equity Partners in 2026, structured as a leveraged buyout (LBO).

What was Polaris’s revenue at the time of the deal?

At the time of the transaction, Polaris’s annual revenue was estimated within the €50–100M range (FY 2025). Detailed financial figures are available to members.

How does the valuation of Polaris compare to benchmarks in the Healthcare & Pharma sector?

Transaction multiples for this specific deal are exclusively reserved for mynth members. Nevertheless, transactions tracked by mynth in this sector reveal an average benchmark multiple of 14.3x EBITDA during 2026.

What sources support the information on this transaction?

The details of this transaction are sourced directly from the official corporate announcement published on the parties’ institutional website, ensuring primary-source verification of the closing and perimeter.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.